A retrospective comparative study shows photon-counting computed tomography delivers higher image quality and reduced radiation doses in multiple myeloma patients.
Bioengineer.org · 14:05
Resumo geral das últimas 24 horas
Nas últimas 24 horas, várias notícias relacionadas com o mieloma múltiplo foram divulgadas. Nos EUA, o National Institutes of Health (NIH) partilhou dados da fase inicial de um tratamento combinado com um anticorpo bispecífico anti-BCMA para mieloma múltiplo recaído/refratário. No Brasil, o estado do Tocantins incorporou um medicamento de alto custo ao tratamento desta doença. Nos EUA, também foi anunciado um subsídio da Pfizer para educação sobre o mieloma múltiplo. Além disso, uma investigação retrospectiva nos Estados Unidos demonstrou que a tomografia computadorizada com contagem de fótons (CT) melhora a qualidade da imagem e reduz a dose de radiação em pacientes com mieloma múltiplo. Outra notícia, também sem país de origem identificado, refere-se a uma lista dos 10 resumos mais importantes a serem apresentados na ASH 2026, focando em terapias como CAR-T e Daratumumab. Adicionalmente, a Tempest Therapeutics adquiriu os direitos de desenvolvimento e comercialização de um tratamento experimental para o mieloma múltiplo. Finalmente, uma publicação no Reino Unido discutiu o alvo da inibição do eixo NFIL3-MYC como uma forma de superar a resistência à terapia no mieloma múltiplo de alto risco.
Feito pela MielomaAI em 17 nov 2026, 15:22. Pode ter erros: abra as notícias e fale com o seu médico.
Só os últimos 3 meses. No site ficam as notícias dos últimos 3 meses. Das mais antigas restam apenas o título e o link, no arquivo por temas, para a pesquisa do site e a MielomaAI as encontrarem.
Recolhidas de jornais portugueses, do Google Notícias (PT, EN, ES, FR) e de associações e sociedades científicas. Estão no site 197 notícias: só as dos últimos 3 meses. As mais antigas ficam apenas com o título e o link, no arquivo por temas, e a pesquisa e a MielomaAI continuam a encontrá-las. Abra sempre a notícia original e fale com o seu médico antes de tirar conclusões sobre o seu caso. Última recolha: 17 nov 2026, 15:21.
A retrospective comparative study shows photon-counting computed tomography delivers higher image quality and reduced radiation doses in multiple myeloma patients.
O artigo fala sobre como o transplante de rim pode ser uma opção para pessoas com mieloma múltiplo e outras doenças que danificam os rins, mas ainda apresenta desafios. Ler mais →
Myeloma Paper of the Day, November 16th, Suggested by Robert Orlowski / Abhishek Gaur, Ankita Gupta, BMC Cardiovascular Disorders, Brendon Staruk, cancer,
Ben Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026 / ASCO, ASH 2026, Ben Derman, cancer, CAR-T, DARA, Daratumumab, Lenalidomide, Mount Sinai,
November 16 2026 Multiple myeloma treatment is expanding across antibody combinations CAR T cell therapies and newer immune modifying drugs Recent U S approvals have brought some options into earlier treatment lines while new subcutaneous formulations are changing how antibody ...
/CNW/ -- Sanofi annonce aujourd'hui l'heureuse conclusion des négociations avec l'Alliance pharmaceutique pancanadienne (APP), marquée par la signature d'une...
Woman Madame Figaro · 12:41 Doentes e associaçõesES
Superviviente de un mieloma múltiple, ha convertido su experiencia con la enfermedad en un compromiso firme para impulsar la investigación oncológica y dar esperanza a miles de pacientes. Por ellos, es nuestra Premio Investigación de los Premios Woman 2026.
El músico de Gandia, en remisión completa del mieloma que le apartó de los escenarios, publica el 24 de noviembre 'A la orilla de Krakatoa', una historia de ficción nacida durante su tratamiento.
The American Journal of Managed Care® (AJMC®) (EUA) · 00:11 TratamentosEUAEN
A single chimeric antigen receptor (CAR) T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.
Rafat Abonour: My Top 10 Interventional Abstracts in Multiple Myeloma and AL Amyloidosis Ahead of ASH 2026 / ASH 2026, ASH26, cancer, multiple myeloma,
Al-Ola A. Abdallah: Four Emerging Research Highlights from ASH26 / Al-Ola A Abdallah, ASH 2026, cancer care, Cancer research, Hematology, Myeloma, OncoDaily
Myeloma Paper of the Day, November 15th, Suggested by Robert Orlowski / Angela Dispenzieri, Blood Cancer Journal, cancer, Daniel G. Packard, David Dingli,
A laboratory study demonstrates that combining mitochondrial complex I inhibitors with proton ionophores selectively triggers apoptosis and disrupts energy balance in multiple myeloma cells in vitro.
CancerNetwork (EUA) · 13:08 Acesso e saúde públicaEUAEN
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
My Treatment Approach: Optimizing Treatment Strategies for Relapsed/Refractory Multiple Myeloma | OncLive Insights | OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Clinical Nurse Specialist - Myeloma at The Clatterbridge Cancer Centre NHS Foundation Trust in Liverpool. £49387-£56515. Temporary Apply on jobs24 today.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Recent advancements in multiple myeloma treatment highlight the promise of trispecific antibodies like JNJ-5322, potentially enhancing patient outcomes significantly.
Peter Voorhees, MD, explains how etentamig differentiates itself from other BCMA bispecifics for multiple myeloma through a strategic engineering choice: a low-affinity CD3 binding domain. By intentionally reducing this affinity, the design aims to mitigate severe cytokine release syndrome. It can also be given on an…
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
SurvivorNet (Reino Unido) · 17:22 Doentes e associaçõesReino UnidoEN
"Lady A" country singer Charles Kelley, 45, says his multiple myeloma treatment is working, but he has been surprised by the physical toll, describing significant pain, body aches, and fatigue during his cancer journey.
In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith explore the potential role of cereblon E3 ligase modulators (CELMoDs) as holding and bridging therapies for patients with multiple myeloma preparing for chimeric antigen receptor (CAR) T-cell therapy.
In this segment, Dr. Joseph Mikhael and Dr. Paul Richardson discuss findings from the phase 3 EXCALIBER-RRMM trial, which compared iberdomide plus daratumumab and dexamethasone with bortezomib plus daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma.
In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss the potential role of cereblon E3 ligase modulators (CELMoDs) following chimeric antigen receptor (CAR) T-cell therapy and in combination with bispecific antibodies for multiple myeloma.
News Farma (Portugal) · 11:39 Doentes e associaçõesPortugal
A Associação Portuguesa Contra a Leucemia (APCL) realiza, no próximo dia 21 de novembro, entre as 09h30 e as 17h20, um seminário dedicado ao mieloma múltiplo (MM), na Escola Artística Conservatório de Música de Coimbra. O encontro reúne doentes, cuidadores, médicos e outros profissionais de saúde, promovendo o diálogo…
O encontro, realizado em formato de curso de imersão, reuniu professores e médicos especialistas na área em uma programação que incluiu aulas, visitas a centros de referência e discussões sobre abordagens diagnósticas e terapêuticas para o mieloma múltiplo, um tipo de câncer que afeta as células plasmáticas da medula…
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D...
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society…
Karyopharm (EUA) · 14:04 Doentes e associaçõesEUAEN
– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026...
The panel discusses treatment strategies for patients with relapsed/refractory multiple myeloma who experience early disease progression following BCMA-directed therapy, including CAR T-cell therapy.
CancerNetwork (EUA) · 08:00 Doentes e associaçõesEUAEN
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith introduce cereblon E3 ligase modulators (CELMoDs) and discuss their dual activity in multiple myeloma.
In this segment, Dr. Joseph Mikhael asks Dr. Scott Goldsmith to explain the evidence supporting the use of minimal residual disease (MRD) negativity as an endpoint for regulatory decision-making in multiple myeloma.
Faculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.
In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how T-cell fitness may influence treatment sequencing in multiple myeloma, particularly as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies become increasingly important treatment options.
A targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy.
Bristol Myers Squibb (Internacional) · 08:00 Doentes e associaçõesInternacionalEN
Multiple myeloma survivors and caregivers helped shape a Brooklyn mural designed to bring their experiences, community connections and stories into public view.
In this segment, Dr. Joseph Mikhael, Dr. Paul Richardson, and Dr. Scott Goldsmith introduce the relationship between minimal residual disease (MRD) negativity and cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting the role of MRD-negative complete response as an emerging regulatory endpoint.
CancerNetwork (EUA) · 08:00 Acesso e saúde públicaEUAEN
Joshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Early Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific Antibodies / Bispecific antibodies, cancer, CAR-T, Headlines,
Nature (Reino Unido) · 08:00 Doentes e associaçõesReino UnidoEN
Multiple myeloma (MM) is a refractory plasma cell neoplasm characterized by frequent development of drug resistance, leading to poor clinical outcomes. Activation of ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, has emerged as a promising cancer therapeutic strategy. In this study, we…
Fred Hutchinson Cancer Center (Reino Unido) · 07:00 TratamentosReino UnidoEN
Rahul Banerjee, MD, FACP joins Petros Grivas, MD, PhD to discuss how CAR T cell-therapy and bispecific antibodies are changing myeloma care, ongoing Fred Hutch trials, working with community oncologists, and the team approach behind it all.
O símbolo junta duas histórias: a do macedotuga.com, de Vila do Conde, e a do mieloma múltiplo.
As cores. O emblema original tem as cores da bandeira de Portugal. Aqui, o verde e o vermelho passaram a dois tons de azul — o azul-claro é a cor associada à saúde.
Os arcos. Em baixo estão os arcos do aqueduto de Santa Clara, em Vila do Conde, a terra onde o Gualter nasceu e para onde regressou em 2017, para enfrentar a doença perto dos seus. Os arcos de Vila do Conde representam a ligação entre todos os que lutam e ajudam os doentes com MM.
As células ligadas. No lugar da esfera armilar estão três plasmócitos — as células da medula óssea onde nasce o mieloma múltiplo. Estão ligados entre si: doentes, cuidadores, médicos e associações. Ninguém deve fazer este caminho sozinho.
MM. Mieloma Múltiplo.
É sempre melhor ser um doente informado. Há esperança. Há caminho.